[{"id":"309d07b0-cac7-4109-a11a-aaa689afa1a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493099","created_at":"2021-01-18T21:35:01.887Z","updated_at":"2024-07-02T16:36:38.833Z","phase":"Phase 1/2","brief_title":"Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML","source_id_and_acronym":"NCT04493099","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • alvocidib (DSP-2033)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 10/12/2020","primary_completion_date":" 10/12/2020","study_txt":" Completion: 10/12/2020","study_completion_date":" 10/12/2020","last_update_posted":"2020-11-11"},{"id":"29b53254-a1d8-4c19-8527-95390b2b9fbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005074","created_at":"2021-01-17T22:57:05.986Z","updated_at":"2024-07-02T16:36:46.345Z","phase":"Phase 2","brief_title":"Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT00005074","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" CD20 • CD5","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alvocidib (DSP-2033)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/24/2000","start_date":" 01/24/2000","primary_txt":" Primary completion: 02/20/2002","primary_completion_date":" 02/20/2002","study_txt":" Completion: 09/22/2008","study_completion_date":" 09/22/2008","last_update_posted":"2020-04-09"},{"id":"04610283-47d7-4091-9c18-1ccd26727c12","acronym":"","url":"https://clinicaltrials.gov/study/NCT00957905","created_at":"2021-01-18T03:43:42.428Z","updated_at":"2024-07-02T16:37:24.527Z","phase":"Phase 2","brief_title":"Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors","source_id_and_acronym":"NCT00957905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • oxaliplatin • leucovorin calcium • alvocidib (DSP-2033) • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-03-10"}]